In collaborative experiments, Draq5 yielded real-time quantitative cell cycle analysis comparable to that obtained using traditional dyes such as Hoechst 34580, Dapi, and propidium iodide
TTP LabTech and Biostatus announce compelling data demonstrating the use of Draq5 DNA dye in binding assays performed with the Acumen eX3 microplate cytometer.
There is an increasing demand for multiplexing in high content assays to maximise data generation and allow correlation across multiple readouts.
However, when fluorescent probes have spectral profiles that overlap, it hinders the degree of multiplexing which can be achieved.
The Acumen eX3 offers 405nm, 488nm and 633nm laser excitation in a single instrument, allowing a wide range of fluorescent probes to be used.
Draq5 is an ideal cell cycle probe since it offers stoichiometric DNA labelling and far-red fluorescent emission when applied to live or fixed cells.
When used in multiplex applications with other fluorophores, such as GFP fusions and FITC-tags, there is an exceptional separation between each emission coupled with minimal spectral emission overlap.
This exciting development offers current and future customers improved multiplexing potential.
Using Draq5 with the Acumen eX3 provides DNA content analysis with fluorescent detection assays across the four detection channels for each laser, giving up to 12 channels for multiplex data.
The screening performance of the Acumen eX3 and the spectral properties of Draq5 make this a strong combination in multiplexed high content screening.
TTP LabTech's chief scientific officer, Wayne Bowen, welcomed the collaborative progression between the two companies, highlighting "the combination of TTP LabTech's expertise in fluorescence detection instrumentation and Biostatus's ability to develop novel reagent technologies creates an excellent opportunity to influence the future of high content multiplex assay analyses".
Roy Edward, sales and marketing director at Biostatus, was delighted at the outcome of this joint effort, adding that "the excellent compatibility of these UK-developed technologies should permit increased information and throughput in fields such as immunology and anti-cancer drug discovery."
